[1]
|
Kiyoi, H. (2019) Acute Myeloid Leukemia: AML. [Rinsho Ketsueki] The Japanese Journal of Clinical Hematology, 60, 224-225.
|
[2]
|
Rallig, C. (2019) Diagnosis and Treatment of Acute Myeloid Leukemia: The Updated 2018 Onkopedia Guideline. Der Internist, 60, 257-272. https://doi.org/10.1007/s00108-019-0562-2
|
[3]
|
Leukemia & Lymphoma Group, Chinese Society of Hematology, Chinese Medical Association (2017) Chinese Guidelines for Diagnosis and Treatment of Adult Acute Myeloid Leukemia (Not APL) (2017). Chinese Journal of Hematology, 38, 177-182.
|
[4]
|
Tallman, M.S., Wang, E.S., Altman, J.K., et al. (2019) Acute Myeloid Leukemia, Version 3. 2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 17, 721-749.
|
[5]
|
Othus, M., Appelbaum, F.R., Petersdorf, S.H., et al. (2015) The Fate of Patients with Newly Diagnosed Acute Myeloid Leukemia Who Fail Primary Induction Therapy. Biology of Blood and Marrow Transplantation, 21, 559-564.
https://doi.org/10.1016/j.bbmt.2014.10.025
|
[6]
|
Fernadez, H.F., Sun, Z., Yao, X., et al. (2009) Anthracycline Dose Intensification in Acute Myeloid Leukemia. New England Journal of Medicine, 361, 1249-1259. https://doi.org/10.1056/NEJMoa0904544
|
[7]
|
Lowenberg, B., Ossenkoppele, G.H., van Putten, W., et al. (2009) High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia. New England Journal of Medicine, 361, 1235-1248.
https://doi.org/10.1056/NEJMoa0901409
|
[8]
|
Estey, E. (2016) Why Are There So Few Randomized Trials for Patients with Primary Refractory Acute Myeloid Leukemia. Best Practice & Research Clinical Haematology, 29, 324-328. https://doi.org/10.1016/j.beha.2016.10.003
|
[9]
|
Kell, J. (2016) Considerations and Challenges for Patients with Refractory and Relapsed Acute Myeloid Leukaemia (Review). Leukemia Research, 47, 149-160. https://doi.org/10.1016/j.leukres.2016.05.025
|
[10]
|
马立元. 成人复发难治性急性髓系白血病治疗进展[J]. 医学与哲学(B), 2018, 39(8): 20-24.
|
[11]
|
O’Donnell, M.R., Tallman, M.S., Abboud, C.N., et al. (2017) Acute Myeloid Leukemia, Version 3. 2017, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network, 15, 926-957.
|
[12]
|
Sternberg, D.W., Aird, W., Neuberg, D., et al. (2000) Treatment of Patients with Recurrent and Primary Refractory Acute Myelogenous Leukemia Using Mitoxantrone and Intermediate-Dose Cytarabine: A Pharmacologically Based Regimen. Cancer, 88, 2037-2041.
https://doi.org/10.1002/(SICI)1097-0142(20000501)88:9<2037::AID-CNCR8>3.0.CO;2-K
|
[13]
|
Breems, D.A., Van Putten, W.L., Huijgens, P.C., et al. (2005) Prognostic Index for Adult Patients with Acute Myeloid Leukemia in First Relapse. Journal of Clinical Oncology, 23, 1969-1978. https://doi.org/10.1200/JCO.2005.06.027
|
[14]
|
Wierzbowska, A., Robak, T., Pluta, A., et al. (2008) Cladribine Combined with High Doses of Arabinoside Cytosine, Mitoxantrone, and G-CSF (CLAG-M) Is a Highly Effective Salvage Regimen in Patients with Refractory and Relapsed Acute Myeloid Leukemia of the Poor Risk: A Final Report of the Polish Adult Leukemia Group. European Journal of Haematology, 80, 115-126. https://doi.org/10.1111/j.1600-0609.2007.00988.x
|
[15]
|
Keating, M.J., Kantarjian, H., Smith, T.L., et al. (1989) Response to Salvage Therapy and Survival after Relapse in Acute Myeloid Leukemia. Journal of Clinical Oncology, 7, 1071-1080. https://doi.org/10.1200/JCO.1989.7.8.1071
|
[16]
|
Gupta, N., Wang, E.S., Freyer, C.W., et al. (2015) Revisiting the Role of Cladribine in Acute Myeloid Leukemia: An Improvement on Past Accomplishments or More Old News? American Journal of Hematology, 90, 62-72.
https://doi.org/10.1002/ajh.23862
|
[17]
|
Robak, T. and Wierzbowska, A. (2014) Cladribine in the Treatment of Acute Myeloid Leukemia. Leukemia Research, 38, 425-427. https://doi.org/10.1016/j.leukres.2014.01.005
|
[18]
|
陈思思, 赵慧慧, 黄佳瑜, 等. CLAG为基础的挽救化疗方案治疗复发难治急性髓系白血病临床观察[J]. 白血病(淋巴瘤), 2019, 28(9): 556-559.
|
[19]
|
(2020) Fludarabine. Lethal Bone Marrow Suppression: Case Report. Reactions Weekly, 1787, 237.
https://doi.org/10.1007/s40278-020-73875-6
|
[20]
|
赵兰滨, 申莲玉. 中剂量阿糖胞苷的FLAG方案治疗难治复发性急性髓系白血病12例临床观察[J]. 中外健康文摘, 2013(4): 135-136.
|
[21]
|
周茉, 单学赟. CLAG方案和MEA方案治疗复发/难治急性髓系白血病的疗效比较[J]. 系统医学, 2018, 3(14): 24-25, 28.
|
[22]
|
刘祥祥, 张涛, 王健红, 等. FLAG和MEA方案治疗难治复发性急性髓系白血病的Meta分析[J]. 现代肿瘤医学, 2019, 27(4): 636-640.
|
[23]
|
罗文丰, 余惠兰, 邹兴立, 等. CLAG方案和FLAG方案治疗难治或复发性急性髓系白血病对比观察[J]. 山东医药, 2018, 58(40): 73-76.
|
[24]
|
刘建平, 郄丽萍, 王向文. 大剂量阿糖胞苷治疗急性白血病的临床观察[J]. 内蒙古医学杂志, 2007, 39(8): 942-943.
|
[25]
|
Christian, S., Patel, P., Esen, A., et al. (2017) A Single Institution Comparison of Mitoxantrone, Etoposide and Cytarabine (MEC) vs High-Dose Cytarabine and Mitoxantrone (ARA-C Couplets) for Treatment of Patients with Relapsed or Refractory Acute Myeloid Leukemia. Blood, 130, 2591. https://doi.org/10.1182/blood-2018-99-111389
|
[26]
|
陈妍, 陈加华. 预激方案治疗低增生性及复发与难治的急性髓系白血病36例临床观察[J]. 中国实用内科杂志, 2012, 32(A2): 24-25.
|
[27]
|
卓丽霞. 地西他滨联合CAG方案治疗难治、复发性急性髓系白血病的疗效观察[J]. 中国实用医药, 2020, 15(5): 149-151.
|
[28]
|
祖璎玲, 张莉, 周健, 等. CAG预激方案联合沙利度胺、干扰素、重组人IL-2治疗难治复发性急性髓系白血病疗效分析[J]. 中华血液学杂志, 2016, 37(4): 334-336.
|
[29]
|
陈琳, 米瑞华, 朱松涛, 等. 西达本胺、地西他滨联合CHAG方案治疗复发难治性急性髓系白血病八例疗效分析[J]. 中华血液学杂志, 2018, 39(7): 602-604.
|
[30]
|
范翠华, 俞文娟, 麦文渊, 等. HAA方案治疗复发难治性急性髓系白血病64例疗效观察[J]. 中华血液学杂志, 2016, 37(2): 100-104.
|
[31]
|
徐玉秀. HAD方案治疗难治复发性急性髓系白血病的疗效观察[J]. 中国实用医药, 2013, 8(15): 78-79.
|
[32]
|
Khan, N., Hantel, A., Knoebel, et al. (2017) Efficacy of Single-Agent Decitabine in Relapsed and Refractory Acute Myeloid Leukemia. Leukemia and Lymphoma, 58, 2127-2133. https://doi.org/10.1080/10428194.2017.1289524
|
[33]
|
Ivanoff, S., Gruson, B., Chantepie, S.P., et al. (2013) 5-Azacytidine Treatment for Relapsed or Refractory Acute Myeloid Leukemia after Intensive Chemotherapy. American Journal of Hematology, 88, 601-605.
https://doi.org/10.1002/ajh.23464
|
[34]
|
Schmidt, E., Mikesch, J.-H., Groth, C., et al. (2017) Allogeneic Transplantation in the Treatment of Acute Leukemia (Review). Onkologe, 23, 543-549. https://doi.org/10.1007/s00761-017-0234-6
|
[35]
|
Bose, P., Vachhani, P. and Cortes, J.E. (2017) Treatment of Relapsed/Refractory Acute Myeloid Leukemia. Current Treatment Options in Oncology, 18, 17. https://doi.org/10.1007/s11864-017-0456-2
|
[36]
|
Su, X.H., Yao, J.F., Zhang, G.X., et al. (2017) Allogeneic Hematopoietic Stem Cell Transplantation for Treatment of Refractory and Relapsed Acute Myeloid Leukemia: Outcomes and Prognostic Factors. Chinese Journal of Hematology, 38, 1024-1030.
|
[37]
|
Vasu, S., Kohlschmidt, J., Mrozek, K., et al. (2018) Ten-Year Outcome of Patients with Acute Myeloid Leukemia Not Treatment with Allogeneic Transplantation in First Complete Remission. Blood Advances, 2, 1645-1650.
https://doi.org/10.1182/bloodadvances.2017015222
|
[38]
|
Tian, H., Chen, G.H., Xu, Y., et al. (2015) Impact of Pre-Transplant Disease Burden on the Outcome of Allogeneic Hematopoietic Stem Cell Transplant in Refractory and Relapsed Acute Myeloid Leukemia: A Single-Center Study. Leukemia & Lymphoma, 56, 1353-1361. https://doi.org/10.3109/10428194.2014.961016
|
[39]
|
Todisco, E., Cieefi, F., Boschini, et al. (2017) Factors Predicting Outcome after Allogeneic Transplant in Refractory Acute Myeloid Leukemia: A Retrospective Analysis of Grnppo Italiano Trapianto di Midollo Osseo (GITMO). Bone Marrow Transplant, 52, 955-961. https://doi.org/10.1038/bmt.2016.325
|
[40]
|
董征, 胡锴勋, 余长林, 等. 单倍体非清髓造血干细胞移植治疗难治复发性白血病的长期随访结果[J]. 中华血液学杂志, 2013, 34(3): 217-220.
|
[41]
|
Smith, C.C. (2019) The Growing Landscape of FLT3 Inhibition in AML. Hematology. American Society of Hematology. Education Program, 2019, 539-547. https://doi.org/10.1182/hematology.2019000058
|
[42]
|
Leick, M.B. and Levis, M.J. (2017) The Future of Targeting FLT3 Activation in AML. Current Hematologic Malignancy Reports, 12, 153-167. https://doi.org/10.1007/s11899-017-0381-2
|
[43]
|
Antar, A.I., Otrock, Z.K., Jabbour, E., et al. (2020) FLT3 Inhibitors in Acute Myeloid Leukemia: Ten Frequently Asked Questions. Leukemia, 34, 682-696. https://doi.org/10.1038/s41375-019-0694-3
|
[44]
|
Robert, R. (2020) The Role of Small Molecule Flt3 Receptor Protein-Tyrosine Kinase Inhibitors in the Treatment of Flt3-Positive Acute Myelogenous Leukemias. Pharmacological Research, 155, Article ID: 104725.
https://doi.org/10.1016/j.phrs.2020.104725
|
[45]
|
Perl, A. (2018) FLT3 Inhibitors in AML. Clinical Lymphoma, Myeloma & Leukemia, 18, S1-S2.
https://doi.org/10.1016/j.clml.2018.06.033
|
[46]
|
Zhang, W., Konopleva, M., Shi, Y., et al. (2008) Mutant FLT3: Sorafenib in Acute Myelogenous Leukemia. Journal of the National Cancer Institute, 100, 184-198. https://doi.org/10.1093/jnci/djm328
|
[47]
|
Zhang, Y., Xuan, L., Fan, Z.P., et al. (2016) Sorafenib as Salvage Therapy in Refractory Relapsed Acute Myeloid Leukemia with Positive FLT3 Mutation. Chinese Journal of Hematology, 37, 292-296.
|
[48]
|
Ravandi, F., Alattar, M.L., Grunwald, M.R., et al. (2013) Phase 2 Study of Azacytidine plus Sorafenib in Patients with Acute Myeloid Leukemia and FLT-3 Internal Tandem Duplication Mutation. Blood, 121, 4655-4662.
https://doi.org/10.1182/blood-2013-01-480228
|
[49]
|
Nazha, A., Kantarjian, H.M., Borthakur, G., et al. (2012) A Phase I/II Trial of Combination of Midostaurin (PKC412) and 5-Azacytidine (5-AZA) for the Treatment of Patients with Refractory or Relapsed (R/R) Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). Blood, 120, 3587. https://doi.org/10.1182/blood.V120.21.3587.3587
|
[50]
|
Levis, M., Ravandi, F., Wang, E.S., et al. (2011) Results from a Randomized Trial of Salvage Chemotherapy Followed by Lestaurtinib for Patients with FLT3 Mutant AML in First Relapse. Blood, 117, 3294-3301.
https://doi.org/10.1182/blood-2010-08-301796
|
[51]
|
Usuki, K., Handa, H., Choi, I., et al. (2019) Safety and Pharmacokinetics of Quizartinib in Japanese Patients with Relapsed or Refractory Acute Myeloid Leukemia in a Phase 1 Study. International Journal of Hematology, 110, 654-664.
https://doi.org/10.1007/s12185-019-02709-8
|
[52]
|
Inaba, H., Panetta, J.C., Buelow, D.R., et al. (2016) Pilot Study of Combined Type I FLT3 Tyrosine Kinase Inhibitor, Crenolanib with Sorafenib in Pediatric Patients with Relapsed/Refractory FLT3+Ve AML. Blood, 128, 3937.
https://doi.org/10.1182/blood.V128.22.3937.3937
|
[53]
|
Reed, D.R., Sen, J.M., Pierce, E.J., et al. (2020) Gilteritinib: An FMS-Like Tyrosine Kinase 3/AXL Tyrosine Kinase Inhibitor for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients. Journal of Oncology Pharmacy Practice, 26, 1200-1212. https://doi.org/10.1177/1078155220918006
|
[54]
|
Mata, R., Subirá, D., García-Raso, A., et al. (2007) Jak2 as a Molecular Marker in Myeloproliferative Diseases. Cardiovascular and Hematological Agents in Medicinal Chemistry, 5, 198-203.
https://doi.org/10.2174/187152507781058654
|
[55]
|
Lee, H.J., Daver, N., Kantarjian, H.M., et al. (2013) The Role of JAK Pathway Dysregulation in the Pathogenesis and Treatment of Acute Myeloid Leukemia. Clinical Cancer Research, 19, 327-335.
https://doi.org/10.1158/1078-0432.CCR-12-2087
|
[56]
|
Pemmaraju, N., Kantarjian, H., Kadia, T, et al. (2015) A Phase I/II Study of the Janus Kinase (JAK)1 and 2 Inhibitor Ruxolitinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma and Leukemia, 15, 171-176. https://doi.org/10.1016/j.clml.2014.08.003
|
[57]
|
Kelly, A.D., Madzo, J., Madireddi, P., et al. (2018) Demethylator Phenotypes in Acute Myeloid Leukemia. Leukemia, 32, 2178-2188. https://doi.org/10.1038/s41375-018-0084-2
|
[58]
|
Zhu, C.-Y., et al. (2015) Clinical Research of Decitabine Combined with Modified CAG Regimen for Treatment of Relapsed or Refractory Acute Myeloid Leukemia. Chinese Journal of Experimental Science, 23, 88-93.
|
[59]
|
Dang, L., Yen, K. and Attar, E.C. (2016) IDH Mutations in Cancer and Progress toward Development of Targeted Therapeutics. Annals of Oncology, 27, 599-608. https://doi.org/10.1093/annonc/mdw013
|
[60]
|
Mondesir, J., Willekens, C., Touat, M., et al. (2016) IDH1 and IDH2 Mutations as Novel Therapeutic Targets: Current Perspectives. Journal of Blood Medicine, 7, 171-180. https://doi.org/10.2147/JBM.S70716
|
[61]
|
Stein, E.M., DiNardo, C.D., Pollyea, D.A., et al. (2017) Enasidenib in Mutant IDH2 Relapsed or Refractory Acute Myeloid Leukemia. Blood, 130, 722-731. https://doi.org/10.1182/blood-2017-04-779405
|
[62]
|
Medeiros, B.C., Fathi, A.T., DiNardo, C.D., et al. (2017) Isocitrate Dehydrogenase Mutations in Myeloid Malignancies. Leukemia, 31, 272-281. https://doi.org/10.1038/leu.2016.275
|
[63]
|
Lagadinou, E.D., Sach, A., Callahan, K., et al. (2013) BCL-2 Inhibition Targets Oxidative Phosphorylation and Selectively Eradicates Quiescent Human Leukemia Stem Cells. Cell Stem Cell, 12, 329-341.
https://doi.org/10.1016/j.stem.2012.12.013
|
[64]
|
DiNardo, C.D., Pratz, K., Pullarkat, V., et al. (2018) Venetoclax Combined with Decitabine or Azacitidine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia. Blood, 133, 7-17.
|
[65]
|
Lehmann, C., Friess, T., Birzele, F., et al. (2016) Superior Anti-Tumor Activity of the MDM2 Antagonist Idasanutlin and the Bcl-2 Inhibitor Venetoclax in p53 Wild-Type Acute Myeloid Leukemia Models. Journal of Hematology & Oncology, 9, 50. https://doi.org/10.1186/s13045-016-0280-3
|
[66]
|
Atrash, S., Bano, K., Harrison, B., et al. (2020) CAR-T Treatment for Hematological Malignancies. Journal of Investigative Medicine. https://doi.org/10.1136/jim-2020-001290
|
[67]
|
Porter, D.L., Levine, B.L., Kalos, M., et al. (2011) Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia. New England Journal of Medicine, 365, 725-733. https://doi.org/10.1056/NEJMoa1103849
|
[68]
|
Davila, M.L., Riviere, I., Wang, X., et al. (2014) Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia. Science Translational Medicine, 6, 224ra25.
|
[69]
|
Rahal, I., Cabannes-Hamy, A. and Boissel, N. (2018) CAR-T Treatment of Acute Leukemia in Adults. Bulletin du Cancer, 105, S158-S167. https://doi.org/10.1016/S0007-4551(19)30046-3
|
[70]
|
Kim, M.Y., Yu, K.-R., Kenderian, S.S., et al. (2018) Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia. Cell, 173, 1439-1453.e19.
|
[71]
|
Galetto, R., Lebuhotel, C., Francon, P., et al. (2015) Allogenic CAR T-Cells Targeting CD123 for Adoptive Immunotherapy of Acute Myeloid Leukemia (AML). Molecular Therapy, 23, S166.
https://doi.org/10.1016/S1525-0016(16)34028-X
|
[72]
|
Wang, Q.S., Wang, Y., Lv, H.-Y., et al. (2015) Treatment of CD33-Directed Chimeric Antigen Receptor-Modified T Cells in One Patient with Relapsed and Refractory Acute Myeloid Leukemia. Molecular Therapy, 23, 184-191.
https://doi.org/10.1038/mt.2014.164
|
[73]
|
Budde, L., Song, J.Y. and Kim, Y. (2017) Remissions of Acute Myeloid Leukemia and Blastic Plasmacytoid Dendritic Cell Neoplasm Following Treatment with CD123-Specific CAR T Cells: A First-in-Human Clinical Trial. Blood, 130, 811.
|